AGF Private Equity
AGF Private Equity is currently one of the leaders in investment capital in France. With more than 2.5 billion Euro under its management, AGF Private Equity is a major actor in corporate financing. AGF Private Equity has been present in European investment capital markets since its beginnings through the AGF Group. The venture capital team has invested in more than 70 companies to date and has a regular, durable investment capacity: more than 50 million Euro are invested each year in young businesses with strong potential, applying an extremely selective methodology. In all, the venture capital team manages more than 400 million Euro. The members of the team play an active role in developing the companies financed by AGF Private Equity funds. AGF Private Equity is the leader or co-leader in investment operations and usually holds a seat on the boards of directors or supervisory boards of the companies financed. While respecting the independence of entrepreneurs and managers, AGF Private Equity contributes its experience in various fields: strategic orientations, growth management, management staff recruitment, technological and commercial partnerships and financial operations.
Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners (EdRIP) is dedicated to minority investments into privately-owned companies. It has currently 750 million Euro under management which are being invested primarily as life sciences venture capital and growth capital. Its life science team of seven professionals has over 90 years of cumulated experience in the life science industry and has a proven track record in biotechnology and medical technology investments. The team has approximately 270 million Euro under management and has recently raised its 155 million Euro BioDiscovery 3 fund. EdRIP is part of the group La Compagnie Financière Edmond de Rothschild, Paris, France. For more information, please visit
www.edrip.fr
InnoBio fund
InnoBio is a French venture capital fund of EUR 140 million, managed by CDC Enterprises and for 37 per cent subscribed by the FSI and leading international pharmaceutical companies established in France such as sanofi-aventis, GSK, Roche, Novartis, Pfizer, Lily, Ipsen, Takeda and Boehringer Ingelheim. The main objective of the fund is to make direct equity and quasi-equity investments in companies that provide innovative technology products and services in the healthcare market. Innobio’s investor team, specialized in this sector and headed by Laurent Arthaud, made its first investment in January 2010.
The FSI and CDC Entreprises
The FSI (Fonds Stratégique d’Investissement) is a limited responsibility company owned 51 per cent by the Caisse des Dépôts and 49 per cent by the French state. It makes equity investments taking minority positions in French companies with projects that create value and enhance competitiveness of the economy.
CDC Entreprises is a management company authorized by France’s financial market regulator, the AMF, and a wholly-owned subsidiary of the Caisse des Dépôts. It makes direct and indirect investments in companies, on a national or regional level, ranging from technology seed funding to small company transmissions. CDC Entreprises manages the investments of the FSI, of the Caisse des Dépôts (now its second largest subscriber) and other public and private institutions investing in small and medium-size French Businesses. Its mission is to encourage the emergence of companies enjoying solid and lasting growth by strengthening their equity capital. Via 180 associated French funds, CDC Entreprises holds more than 2,500 companies in its portfolio.
www.fonds-fsi.fr -
www.cdcentreprises.fr –
www.france-investissement.fr
Amundi Private Equity Funds
Amundi Private Equity Funds (Amundi PEF) was born of the merger of the non-listed venture capital and infrastructure businesses of CAAM and SGAM. With assets under management of €3.8 billion at 31 December 2009, Amundi PEF offers its retail and institutional clients an extensive range of products tailored to their needs and giving them access to private equity and infrastructure funds of funds as well as private equity funds dedicated to direct shareholdings in non-listed companies. With over 60 investment professionals based in Paris, Bucharest, Casablanca, Tunis and Warsaw, Amundi PEF helps companies at every stage of their growth, from creation to transmission, and forms long-standing and trusting relationships with its clients.
Amundi PEF is an expertise of the Amundi Group.
www.amundi-pef.com
IRDI
Based in Toulouse, IRDI is regional investment firm. Since 1981, the team has played a leadership role in providing capital to growing companies located in south-West of France. Through a family of private equity funds totalling more than 300 m Euro under management, the team is active in Venture and Expansion capital and also in LBO transactions. For more information:
www.irdi.fr Contact : Jean-Michel Petit at +33 (0)5-61-417-408 ;
jean.michel.petit@irdi.fr
